These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

400 related articles for article (PubMed ID: 26017871)

  • 1. SPIRONOLACTONE FOR NONRESOLVING CENTRAL SEROUS CHORIORETINOPATHY: A RANDOMIZED CONTROLLED CROSSOVER STUDY.
    Bousquet E; Beydoun T; Rothschild PR; Bergin C; Zhao M; Batista R; Brandely ML; Couraud B; Farman N; Gaudric A; Chast F; Behar-Cohen F
    Retina; 2015 Dec; 35(12):2505-15. PubMed ID: 26017871
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mineralocorticoid receptor antagonism in the treatment of chronic central serous chorioretinopathy: a pilot study.
    Bousquet E; Beydoun T; Zhao M; Hassan L; Offret O; Behar-Cohen F
    Retina; 2013; 33(10):2096-102. PubMed ID: 23719402
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Eplerenone for chronic central serous chorioretinopathy-a randomized controlled prospective study.
    Schwartz R; Habot-Wilner Z; Martinez MR; Nutman A; Goldenberg D; Cohen S; Shulman S; Guzner-Gur H; Loewenstein A; Goldstein M
    Acta Ophthalmol; 2017 Nov; 95(7):e610-e618. PubMed ID: 28653813
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROL PILOT STUDY OF EPLERENONE FOR THE TREATMENT OF CENTRAL SEROUS CHORIORETINOPATHY (ECSELSIOR).
    Rahimy E; Pitcher JD; Hsu J; Adam MK; Shahlaee A; Samara WA; Vander JF; Kaiser RS; Chiang A; Spirn MJ; Fineman MS
    Retina; 2018 May; 38(5):962-969. PubMed ID: 28426624
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CENTRAL SEROUS CHORIORETINOPATHY TREATED WITH MINERALOCORTICOID ANTAGONISTS: A ONE-YEAR PILOT STUDY.
    Ghadiali Q; Jung JJ; Yu S; Patel SN; Yannuzzi LA
    Retina; 2016 Mar; 36(3):611-8. PubMed ID: 26405766
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Spironolactone versus observation in the treatment of acute central serous chorioretinopathy.
    Sun X; Shuai Y; Fang W; Li J; Ge W; Yuan S; Liu Q
    Br J Ophthalmol; 2018 Aug; 102(8):1060-1065. PubMed ID: 29089356
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MINERALOCORTICOID RECEPTOR ANTAGONIST TREATMENT IN BILATERAL CHRONIC CENTRAL SEROUS CHORIORETINOPATHY: A COMPARATIVE STUDY OF EXUDATIVE AND NONEXUDATIVE FELLOW EYES.
    Gergely R; Kovács I; Schneider M; Resch M; Papp A; Récsán Z; Nagy ZZ; Ecsedy M
    Retina; 2017 Jun; 37(6):1084-1091. PubMed ID: 27627749
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictive Factors of Response to Mineralocorticoid Receptor Antagonists in Nonresolving Central Serous Chorioretinopathy.
    Bousquet E; Dhundass M; Lejoyeux R; Shinojima A; Krivosic V; Mrejen S; Gaudric A; Tadayoni R
    Am J Ophthalmol; 2019 Feb; 198():80-87. PubMed ID: 30308202
    [TBL] [Abstract][Full Text] [Related]  

  • 9. COMPARISON OF SHORT-TERM EFFICACY BETWEEN ORAL SPIRONOLACTONE TREATMENT AND PHOTODYNAMIC THERAPY FOR THE TREATMENT OF NONRESOLVING CENTRAL SEROUS CHORIORETINOPATHY.
    Lee JH; Lee SC; Kim H; Lee CS
    Retina; 2019 Jan; 39(1):127-133. PubMed ID: 29095358
    [TBL] [Abstract][Full Text] [Related]  

  • 10. COMPARISON OF VISUAL/ANATOMICAL OUTCOMES AND RECURRENCE RATE BETWEEN ORAL SPIRONOLACTONE AND PHOTODYNAMIC THERAPY FOR NONRESOLVING CENTRAL SEROUS CHORIORETINOPATHY.
    Kim DY; Lee JY; Lee EK; Kim JY
    Retina; 2020 Jun; 40(6):1191-1199. PubMed ID: 30897068
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Eplerenone treatment in chronic central serous chorioretinopathy].
    Sampo M; Soler V; Gascon P; Ho Wang Yin G; Hoffart L; Denis D; Matonti F
    J Fr Ophtalmol; 2016 Jun; 39(6):535-42. PubMed ID: 27230892
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mineralocorticoid Receptor Antagonists in Central Serous Chorioretinopathy: A Meta-Analysis of Randomized Controlled Trials.
    Wang SK; Sun P; Tandias RM; Seto BK; Arroyo JG
    Ophthalmol Retina; 2019 Feb; 3(2):154-160. PubMed ID: 31014765
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The use of mineralocorticoid receptor antagonists in chronic central serous chorioretinopathy.
    Pociej-Marciak W; Karska-Basta I; Ozog-Baran J; Kubicka-Trzaska A; Filemonowicz-Skoczek A; Romanowska-Dixon B
    Klin Oczna; 2016 Aug; 118(1):48-54. PubMed ID: 29715409
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral eplerenone for treatment of chronic central serous chorioretinopathy: a case series.
    Salz DA; Pitcher JD; Hsu J; Regillo CD; Fineman MS; Elliott KS; Vander JF; Fischer DH; Spirn MJ
    Ophthalmic Surg Lasers Imaging Retina; 2015 Apr; 46(4):439-44. PubMed ID: 25970864
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The use of eplerenone in therapy-resistant chronic central serous chorioretinopathy.
    Breukink MB; den Hollander AI; Keunen JE; Boon CJ; Hoyng CB
    Acta Ophthalmol; 2014 Sep; 92(6):e488-90. PubMed ID: 24698599
    [No Abstract]   [Full Text] [Related]  

  • 16. Two-year follow-up of mineralocorticoid receptor antagonists for chronic central serous chorioretinopathy.
    Zola M; Daruich A; Matet A; Mantel I; Behar-Cohen F
    Br J Ophthalmol; 2019 Aug; 103(8):1184-1189. PubMed ID: 30355720
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SPIRONOLACTONE AS A THERAPEUTIC ALTERNATIVE FOR THE BULLOUS VARIANT OF CENTRAL SEROUS CHORIORETINOPATHY.
    Ramos-Yau EC; Muñoz-Domínguez E; Contreras-Mérida SP; Valencia-Londoño LM
    Retin Cases Brief Rep; 2020; 14(4):381-385. PubMed ID: 29595560
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical experience with eplerenone to treat chronic central serous chorioretinopathy.
    Cakir B; Fischer F; Ehlken C; Bühler A; Stahl A; Schlunck G; Böhringer D; Agostini H; Lange C
    Graefes Arch Clin Exp Ophthalmol; 2016 Nov; 254(11):2151-2157. PubMed ID: 27145785
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral Mineralocorticoid-Receptor Antagonists: Choroidal Parameters Changes Using OCT in Central Serous Chorioretinopathy.
    Faghihi H; Mohammadzadeh V; Nabavi A; Faghihi S; Kadivar S; Ghassemi F
    Ophthalmic Surg Lasers Imaging Retina; 2019 Nov; 50(11):726-733. PubMed ID: 31755972
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term results and recurrence rates after spironolactone treatment in non-resolving central serous chorio-retinopathy (CSCR).
    Herold TR; Rist K; Priglinger SG; Ulbig MW; Wolf A
    Graefes Arch Clin Exp Ophthalmol; 2017 Feb; 255(2):221-229. PubMed ID: 27475933
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.